Learn

A summary of a recent presentation titled; Australian experience with cariprazine: A case-based discussion considering the use of cariprazine in the management of schizophrenia in adults. The presentation was made by Dr Matthew Warden who highlights the changing schizophrenia treatment landscape and the evolution of treatment goals. Moreover, he discussed cariprazine, a D2/D3 receptor partial agonist antipsychotic with preferential binding to D3, using clinical data and schizophrenia case studies.

Details

The speaker included Dr Matthew Warden brings significant experience across public and private mental health services in both Australia and the UK. His previous roles include Director of Acute Inpatient Services, ECT and MHA governance at St Vincent's Hospital, Melbourne; Consultant Psychiatrist in the Hobart and Southern Districts Community Mental Health Team, Tasmania; and a member of the Mental Health Act Tribunal in Tasmania.

This activity is accepted by CPD Home as a Domain 1: Educational Activity - Professional Reading in alignment with the CPD Home Program Guide. 

Disclaimer: Please note, once you click 'Enrol now' you will be leaving the AMA’s CPD Home website and entering a third-party website.